Skip to Content

'
Raymond Alexanian, M.D.

Present Title & Affiliation

N/A

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 429
Houston, TX 77030
Room Number: FC6.2042
Phone: 713-792-2860
Fax: 713-563-5067
Email: ralexani@mdanderson.org

Education & Training

Degree-Granting Education

1955 Harvard Medical School, Boston, MA, MD, Medicine
1953 Dartmouth Medical School, Hanover, NH, Transferred, Medicine
1952 Dartmouth College, Hanover, NH, AB, Business

Postgraduate Training

1962-1963 Research Fellowship, Radiobiology, Christie Hospital and Holt Radium Institute, Manchester, England, Dr. Laszlo Lajtha
1960-1962 Research Fellowship, Hematology, University of Washington School of Medicine, Seattle, WA, Dr. Clement Finch
1958-1960 Clinical Residency, University of Washington School of Medicine, Seattle, WA, Dr. Robert Williams
1955-1956 Clinical Internship, King County Hospital, Seattle, WA

Board Certifications

8/1966 American Board of Internal Medicine

Experience/Service

Academic Appointments

Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1975-present
Associate Professor, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1966-1975
Assistant Professor, The University of Tesas M.D. Anderon Cancer Center, Houston, TX, 1964-1966
Research Instructor, University of Washington School of Medicine, Seattle, WA, 1963-1964

Selected Publications

Peer-Reviewed Original Research Articles
1. Wang M, Giralt S, Delsalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 12(3):235-239, 2007. PMID: 17558699.
2. Weber D, Thomas S, Wang M, Alexanian R. Rituximab alone or in combination in the frontline treatment of Waldenstrom's macroglobulinemia. Haematologica 92((s2)):87-88, 2007.
3. Alexanian R, Weber D. Solitary bone and extramedullary plasmacytoma. Haematologica 92((s2)):57-58, 2007.
4. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limenstani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24(19):3113-3120, 2006. e-Pub 6/5/2006. PMID: 16754936.
5. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal B, Estrov Z. Atiprimod blocks STAT3 phophorylation and induces apoptosis in multiple myeloma cells. British Journal of Cancer 93:70-80, 2005.
6. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalov G, Orlowski RZ, Richardson PG, Anderson N, Nix I, Esseltine DL, Anderson KC. Bortezomib in recurrent and/or refractory multiple myeloma. Cancer 103:1195-2000, 2005.
7. Dimopoulos MA, Merlini G, Leblond V, Anagnostopoulos A, Alexanian R. How we treat Waldenstrom's macroglobulinemia. Haematologica 90:117-125, 2005.
8. Berenson J, Jagannath S, Barlogie B, Siegel D, Alexanian R, Richardson P, Irwin D, Alsina M, Rajkumar S, Srkolovic G, Singhal S, Limentani S, Niesvizky R, Esseltine D, Trehu E, Schenkein D, Anderson K. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 104(10):2141-2148, 2005. PMID: 16206291.
9. Wang M, Weber D, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 79(3):194-197, 2005. PMID: 15981221.
10. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentari SA, Alsina M, Adams J, Kauffman M, Esseltine D, Schenkein D, Anderson K. A phase 2 study of two doses of bortezomib in relapsed. British Journal of Haematology 127:165-172, 2004.
11. Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 34(3):229-234, 2004. PMID: 15170166.
12. Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt S. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cychlophophamide for patients with multiple myeloma. Cancer 100:2607-2612, 2004.
13. Donato MI, Aleman A, Champlin RE, Weber D, Alexanian R, Ippoliti CM, de Lima M, Anagnostopoulos A, Giralt S. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma 45(4):755-759, 2004. PMID: 15160952.
14. Bharti A, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-(kappa) B and STAT3 are constitutively active in CD138+cells derived from multiple myeloma patients, and their suppression leads to apoptosis. Blood 103:3175-3184, 2004.
15. Anagnostopoulos A, Aleman A, Yang Y, Donato M, Weber D, Champlin R, Smith T, Alexanian R, Giralt S. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone in patients with multiple myeloma who received dexamethasone-based nonmyelosuppresive induction therapy. Bone Marrow Transplantation 33:623-628, 2004.
16. Dimopoulos MA, Alexanian R, Gika D, Anagnostopoulos A, Zervas C, Zomas A, Kyrtsonis MC, Anagnastopoulos N, Pangalis Ga, Weber DM. Treatment of Waldenstrom's macroglobulinemia with rituximab: prgonostic factors for reponse and progression. Leukemia & Lymphoma 45:2057-2061, 2004.
17. Weber D, Dimopoulos M, Delasalle K, Rankin K, Alexanian R. 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 30(2):243-247, 2003. PMID: 12720145.
18. Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar S, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski R, Kuter D, Limentani S, Lee S, Hideshima T, Esseltine D, Kauffman M, Adams J, Schenkein D, Anderson K. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609-2617, 2003. PMID: 12826635.
19. Alexanian R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M. Asymptomatic Waldenstrom's macroglobulinemia. Semin Oncol 30(2):206-210, 2003. PMID: 12720137.
20. Giralt S, Bensinger W, Goodman M, Podoloff D, Earv J, Wendt R, Alexanian R, Weber D, Holmberg L, Rajandran J, Breitz H, Ghalie R, Champlin R. HO-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma. Blood 102:2684-2691, 2003.
21. Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, Lister T, Merlini G, Morel P, Stone M, Branagan A, Leblond V. Prognostic markers and criteria to initiate therapy in Wadenstrom's macroglobulinemia. Seminars in Oncology 30:116-120, 2003.
22. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 13(7):1116-1119, 2002. PMID: 12176792.
23. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Veno N, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30(6):367-373, 2002. PMID: 12235521.
24. Wilder R, Ha C, Cox J, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 94(5):1532-1537, 2002. PMID: 11920511.
25. Mansoor A, Medeiros J, Weber D, Alexanian R, Hayes K, Jones D, Lai R, Glassman A, Bueso-Ramos C. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenstrom's macroglobulimia. Amer J Clin Pathol 116:543-549, 2001.
26. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, Champlin R. Impact of complete remisission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Tranplantation 27:1037-1043, 2001.
27. Alexanian R, Weber D, Dimopoulos M, Delasalle K, Smith T. Randomized trial of a-interferon or dexamethasone as maintenance treatmetn for multiple myeloma. Amer J Hemat 65:204-209, 2000.
28. Alexanian R, Weber D. Thalidomide for resistant and relapsing myeloma. Seminars in Hematology 37(1):22-25, 2000.
29. Bergsagel D, Wong O, Bergsagel P, Delasalle K, Alexanian R. Benzene and multiple myeloma: appraisal of the scientific evidence. Blood 94(4):1174-1182, 1999. PMID: 10438704.
30. Liebross R, Ha C, Cox J, Weber D, Delasalle K, Alexanian R. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol 52(3):245-249, 1999. PMID: 10580871.
31. Alexanian R, Weber D, Liu F. Differential diagnosis of monoclonal gammopathies. Arch Pathol Lab Med 123(2):108-113, 1999. PMID: 10050782.
32. Keren D, Alexanian R, Goeken J, Gorevic P, Kyle R, Tomar R. Guidelines for clinical and laboratory evolution of patients with monoclonal gammopathies. Arch Pathol Lab Med 123:106-107, 1999.
33. Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J, Tricot G, Alexanian R. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 21(11):1101-1108, 1998. PMID: 9645572.
34. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian R. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 101(1):189-194, 1998. PMID: 9576200.
35. Liebross R, Ha C, Cox J, Weber D, Delasalle K, Alexanian R. Solitary bone plasmacytoma: Outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys 41(5):1063-1067, 1998. PMID: 9719116.
36. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, Gajewski J, Andersson B, Khousi I, Przepiorka D, von Wolff B, Delasalle K, Korbling M, Seong D, Alexanian R, Champlin R. Phase I trial of cyclosporine-induced graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 15:667-673, 1997.
37. Dimopoulos M, Weber D, Kantarjian H, Delasalle K, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol 52(2):77-81, 1996. PMID: 8638645.
38. Alexanian R, Weber D. Whither interferon for myeloma and other hematologic malignancies. Ann Intern Med 124(2):264-265, 1996. PMID: 8534004.
39. Daliani D, Weber D, Alexanian R. Light-heavy chain deposition disease progressing to multiple myeloma. Am J Hematol 50(4):296-298, 1995. PMID: 7485106.
40. Moulopoulos L, Dimopoulos M, Smith T, Weber D, Delasalle K, Libshitz H, Alexanian R. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 13(1):251-256, 1995. PMID: 7799027.
41. Dimopoulos M, Weber D, Delasalle K, Keating M, Alexanian R. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine. Annals of Oncology 6:49-52, 1995.
42. Weber D, Dimopoulos M, Sinicrope F, Alexanian R. VAD-cyclosporine therapy for VAD-resistant multiple myeloma. Leuk Lymphoma 19(1-2):159-163, 1995. PMID: 8574163.
43. Dimopoulos M, Weber D, Kantarjian H, Keating M, Alexanian R. 2 Chlorodeoxyadenosine therapy of patients with Waldenstrom macroglobulinemia previously treated with fludarabine. Annals of Oncology 5:288-289, 1994.
44. Alexanian R, Dimopoulos M, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood 84(12):4278-4282, 1994. PMID: 7994043.
45. Vesole D, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, Crowley J. High-dose therapy for refractory multiple myeloma. Blood 84:950-956, 1994.
46. Dimopoulos M, Hester J, Huh Y, Champlin R, Alexanian R. Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol 87(4):730-734, 1994. PMID: 7986714.
47. Alexanian R, Dimopoulos M, Smith T, Delasalle K, Barlogie B, and Champlin R. Limited value of myeloblative therapy for late multiple myeloma. Blood 83:512-516, 1994.
48. Moulopoulos L, Dimopoulos M, Alexanian R, Leeds N, Libshitz H. Multiple myeloma: MR patterns of response to treatment. Radiology 193(2):441, 1994. PMID: 7972760.
49. Dimopoulos M, Palumbo A, Delasalle K, Alexanian R. Primary plasma cell leukemia. Brit J Haemat 88:754-759, 1994.
50. Dimopoulos M, Arbuck S, Huber M, Weber D, Luckett R, Delasalle K, Alexanian R. Primary therapy of multiple myeloma with paclitaxol (Taxol). Annals of Oncology 5:757-759, 1994.
51. Dimopoulos M, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12:2694-2698, 1994.
52. Dimopoulos M, Alexanian R. Waldenstrom's macroglobulinemia. Blood 83(6):1452-1459, 1994. PMID: 8123836.
53. Dimopoulos M, Weber D, Delasalle K, Alexanian R. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma. Cancer 72(9):2589-2592, 1993. PMID: 8402480.
54. Dimopoulos M, Delasalle K, Champlin R, Alexanian R. Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. Br J Haematol 83(2):240-244, 1993. PMID: 8457473.
55. Dimopoulos M, O'Brien S, Kantarjian H, Pierce S, Delasalle K, Barlogie B R, Alexanian R, Keating M. Dimopoulos M, O'Brien S, Kantarjian H, Pierce S, Delasalle K, Barlogie B R, Alexanian R, Keating M. Fludarabine therapy in Waldenstrom's macroglobulinemia 95:49-52, 1993.
56. Moulopoulos L, Granfield C, Dimopoulos M, Kim E, Alexanian R, Libshitz H. Extraosseous multiple myeloma: Imaging features. AJR Am J Roentgenol 161(5):1083-1087, 1993. PMID: 8273615.
57. Moulopoulos L, Dimopoulos M, Weber D, Fuller L, Libshitz H, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 11(7):1311-1315, 1993. PMID: 8315427.
58. Dimopoulos M, Moulopoulos A, Smith T, Delasalle K, Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med 61(1):57-61, 1993. PMID: 8420300.
59. Dimopoulos M, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, van Besien K, Delasalle K, Reading C, Deisseroth A, Champlin R. Thiotepa, busulfan and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem transplantation in high-risk multiple myeloma. Blood 82:2324-2328, 1993.
60. Dimopoulos M, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating M, Freireich E, Alexanian R. Treatment of waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 118(3):195-198, 1993. PMID: 8093333.
61. Dimopoulos M, Goldstein J, Fuller L, Delasalle K, Alexanian R. Curability of solitary bone plasmacytoma. J Clin Oncol 10(4):587-590, 1992. PMID: 1548521.
62. Moulopoulos L, Varma D, Dimopoulos M, Leeds N, Kim E, Johnston D, Alexanian R, Libshitz H. Multiple myeloma: Spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 185(3):833-840, 1992. PMID: 1438772.
63. Alexanian R, Dimopoulos M, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 80(4):887-890, 1992. PMID: 1498331.
64. Alexanian R, Barlogie B, Gutterman J. Alexanian R, Barlogie B, Gutterman J. Alpha-interferon combination therapy of resistant myeloma 14:188-192, 1991.
65. Dimopoulos M, Barlogie B, Smith T, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 115(12):931-935, 1991. PMID: 1952489.
66. Seider M, Cleary K, van Tassel P, Alexanian R, Schantz S, Frias A, Fuller L. Plasma cell granuloma of the nasal cavity treated by radiation therapy. Cancer 67(4):929-932, 1991. PMID: 1789819.
67. Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson B, Lemaistre F, Smallwood L, Pruitt K, Dixon D. Autologous bone marrow transplantation in multiple myeloma. Blood 76:1860-1866, 1990.
68. Kantarjian H, Alexanian R, Koller C, Kurzrock R, Keating M. Fludarabine therapy in macroglobulinemic lymphoma. Blood 75(10):1928-1931, 1990. PMID: 1692487.
69. Ventura G, Barlogie B, Hester J, Yau J, LeMaistre C, Wallerstein R, Spinolo J, Dicke K, Horwitz L, Alexanian R. High dose cyclophophamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma. Bone Marrow Transplantation 5:265-268, 1990.
70. Barlogie B, Jagannath S, Dixon D, Cheson B, Smallwood L, Hendrickson A, Purvis J, Bonnem E, Alexanian R. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 1990(4):677-680, 1990. PMID: 2200536.
71. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Arch Int Med 50:1693-1695, 1990.
72. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33(2):86-89, 1990. PMID: 2301376.
73. Barlogie B, Velasquez W, Alexanian R, Cabanillas F. Etoposide, dexamethasone, cytosine arabinoside and cisplatin in VAD-refractory myeloma. J Clin Oncology 7:1514-1517, 1989.
74. Barlogie B, Smallwood L, Smith T, Alexanian R. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med 110(7):521-525, 1989. PMID: 2647015.
75. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma new biological insights and advances in therapy (editorial). Blood 73:865-879, 1989.
76. Alexanian R, Barlogie B, Dixon D. Alexanian R, Barlogie B, Dixon D. Prognosis of asympotomatic multiple myeloma 148:1963-1965, 1988.
77. Selvanayagan P, Blick M, Narni F, van Tuinen P, Ledbetter D, Alexanian R, Saunders G, Barlogie B. Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma. Blood 71(1):30-35, 1988. PMID: 3275475.
78. Tsuchiya H, Epstein J, Selvanayagam P, Dedman J, Gallic G, Alexanian R, Barlogie B. Correlated flow cytometric analysis of H-ras p 21 and nuclear DNA in multiple myeloma. Blood 72(2):796-800, 1988. PMID: 3042048.
79. Lorigan J, David C, Shirkhoda A, Eftekhari F, Alexanian R. Macroglobulinaemic lymphoma presenting with perirenal masses. Br J Radiol 61(731):1077-1078, 1988. PMID: 3061549.
80. Epstein J, Barlogie B, Katzmann J, Alexanian R. Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement. Blood 71(4):861-865, 1988. PMID: 2451550.
81. Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B. Plasma cell kerotype in multiple myeloma. Blood 71:453-456, 1988.
82. Barlogie B, Alexanian R, Smallwood L, Cheson B, Dixon D, Dicke K, Cabanillas F. Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood 72(6):2015-2019, 1988. PMID: 3196876.
83. Quesada J, Alexanian R, Kurzrock R, Barlogie B, Saks S, Gutterman J. Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia. Am J Hematol 29(1):1-4, 1988. PMID: 3140655.
84. Barlogie B, Alexanian R, Dicke K, Zagars G, Spitzer G, Jagannath S, Horowitz L. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70(3):869-872, 1987. PMID: 3304465.
85. Smith L, Barlogie B, Alexanian R. Biclonal and hypodiploid multiple myeloma. Am J Med 80(5):841-843, 1986. PMID: 3706371.
86. Quesada J, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, Gutterman J. Gutterman J: Treatment of multiple myeloma with recombinant alpha interferon. Blood 67:275-286, 1986.
87. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67(5):1298-1301, 1986. PMID: 3516252.
88. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment for resistant myeloma. Ann Int Med 105:8-11, 1986.
89. Alexanian R, Barlogie B, Fritsche H. Beta2microglobulin in multiple myeloma. Am J Hematol 20(4):345-352, 1985. PMID: 3907332.
90. Barlogie B, Alexanian R, Pershouse M, Smallwood L, Smith L. Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest 76(2):765-769, 1985. PMCID: PMC423897.
91. Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, Delasalle K. Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 66(2):338-341, 1985. PMID: 2410065.
92. Bonnet J, Alexanian R, Salmon SE, Haut A, Dixon D. Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma. Cancer Treat Rep 68:481-485, 1984.
93. Alexanian R, Fraschini G, Smith L. Amyloidosis (AL) in multiple myeloma or without apparent cause. Arch Int Med 144:2158-2160, 1984.
94. Alexanian R, Dreicer R. Chemotherapy for multiple myeloma. Cancer 53(3):583-588, 1984. PMID: 6362819.
95. Quesada J, Hawkins, Horning S, Alexanian R, Borden E, Merigan T, Adams F, Gutterman J. Collaborative Phase I-II study of recombinant DNA-produced leukocyte interferon (Clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am J Med 77(3):427-432, 1984. PMID: 6548079.
96. Tula CJ, Berman L, Alexanian R. Connective tissue disease manifested as multiple myeloma. South Med J 77(12):1580-1581, 1984. PMID: 6209804.
97. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310(21):1353-1356, 1984. PMID: 6546971.
98. Kantarjian H, Dreicer R, Barlogie B, Plunkett W, Alexanian R. High-dose cytosine arabinoside in multiple myeloma. Eur J Cancer Clin Oncol 20(2):227-231, 1984. PMID: 6538488.
99. Foucar K, Raber M, Foucar E, Barlogie B, Sandler C, Alexanian R. Anaplastic myeloma with massive extramedullary involvement: Report of two cases. Cancer 51(1):166-174, 1983. PMID: 6336972.
100. Barlogie G, Alexanian R, Gehan E, Smallwood L, Smith T, Drewinko B. Marrow cytometry and prognosis in myeloma. J Clin Invest 72(3):853-861, 1983. PMCID: PMC1129250.
101. Alexanian R, Yap BS, Bodey GP. Prednisone pulse therapy for refractory myeloma. Blood 62(3):572-577, 1983. PMID: 6882916.
102. McLaughlin P, Alexanian R. Myeloma protein kinetics following chemotherapy. Blood 60(4):851-855, 1982. PMID: 7115956.
103. Dreicer R, Alexanian R. Nonsecretory multiple myeloma. Am J Hematol 13(4):313-318, 1982. PMID: 7158626.
104. Latreille J, Barlogie B, Johnston D, Drewinko B, Alexanian R. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood 59(1):43-51, 1982. PMID: 6172171.
105. Gutterman JU, Fein S, Quesada J, Horning SJ, Levine JF, Alexanian R, et al. Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance and biologic effects in cancer patients. Ann Intern Med 96(5):549, 1982. PMID: 6176159.
106. Alexanian R, Salmon S, Gutterman J, Bonnet J, Dixon D, Haut A. Chemoimmunotherapy for multiple myeloma. Cancer 47(8):1923-1929, 1981. PMID: 7226087.
107. Drewinko B, Boyer H, Alexanian, et al:. The growth fraction of human myeloma cells. Blood 57(2):333-338, 1981. PMID: 7448427.
108. Latreille J, Barlogie B, Dosik G, Johnston DA, Drewinko B, Alexanian R. Cellular DNA content as a marker of human multiple myeloma. Blood 55(3):403-409, 3/1980. e-Pub 1980. PMID: 7357078.
109. Gutterman J, Blumenschein G, Alexanian R, et al:. Leukocyte interferon induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 93(3):399-406, 1980. PMID: 6159812.
110. Alexanian R. Localized and indolent myeloma. Blood 56(3):521-526, 1980. PMID: 7407416.
111. Alexanian R, Gehan E, Haut A, Saiki J, Weick J. Unmainted remission in multiple myeloma. Blood 51:1005-1011, 1978.
112. Gonzales F, Trujillo JM, Alexanian R. Acute leukemia in multiple myeloma. Ann Intern Med 86(4):440-443, 1977. PMID: 403840.
113. Alexanian R. Blood volume in monoclonal gammopathy. Blood 49(2):301-307, 1977. PMID: 401657.
114. Bodey GP, Gottleib JA, Burgess MA, Alexanian R. Clinical evaluation of asaley. Med Pediatr Oncol 3(4):365-371, 1977. PMID: 927333.
115. Alexanian R, Salmon S, Bonnet J, Gehan E, Haut A, Weick J. Combination therapy for multiple myeloma. Cancer 40(6):2765-2771, 1977. PMID: 589554.
116. Drewinko B, Alexanian R. Growth kinetics of plasma cell myeloma. J Natl Cancer Inst 58(5):1247-1253, 1977. PMID: 857025.
117. Alexanian R, Alfrey C. Erythrokinetics and androgens in bone marrow cancer. Cancer 38(2):833-840, 1976. PMID: 975001.
118. Alexanian R, Balcerzark S, Bonnet J, Gehan E, Haut A, Hewlett J, Monto R. Prognostic factors in multiple myeloma. Cancer 36(4):1192-1201, 1975. PMID: 1175123.
119. Alexanian R, Balcerzark S, Bonnet J, Gehan E, Haut A, Hewlett J, Monto R. Prognostic factors in multiple myeloma. Cancer 36:1192-1201, 1975.
120. Mavligit GM, Gutterman JV, Hersh EM, Alexanian R. Cell-mediated immunity to plasma cell myeloma: Specific inhibition by a serum factor adhering to effector lymphocytes. Proc Soc Exp Biol Med 147(2):537, 11/1974. PMID: 4280077.
121. Drewinko B, Brown BW, Humphrey R, Alexanian R. Effect of chemotherapy on the labeling index of myeloma cells. Cancer 34:526-531, 1974.
122. Rodriguez LH, Finkelstein JB, Shullenberger CC, Alexanian R. Bone healing in multiple myeloma from melphalan chemotherapy. Ann Int Med 75:551-556, 1972.
123. Alexanian R, Bonnet J, Gehan E, Haut A, Hewlett J, Lane M, Monto R, Wilson H. Combination chemotherapy for multiple myeloma. Cancer 30(2):382-389, 1972. PMID: 5051662.
124. Alexanian R. Erythropoietin excretion in bone marrow failure and hemolytic anemia. J Lab Clin Med 83(3):438-445, 1972. PMID: 4728292.
125. Alexanian R, Nadell J. Oxymetholone treatment for sickle cell anemia. Blood 45(6):769-777, 1972. PMID: 1125426.
126. Harris J, Alexanian R, Hersh E, Migliore P. Immune function in multiple myeloma: Impaired responsiveness to keyhole limpet homocyanin. Canad Med Assn 104:389-393, 1971.
127. Alexanian R, Alfrey C. Erythropoiesis in the anemia of bone marrow failure. J Clin Invest 49(11):1986-1992, 1970. PMCID: PMC535776.
128. Moore DF, Migliore P, Shullenberger CC, Alexanian R. Monoclonal macroglobulinemia in malignant lymphoma. Ann Intern Med 72(1):43-47, 1970. PMID: 4983128.
129. Alexanian R, Migliore P. Normal immunoglobulins in multiple myeloma. J Lab Clin Med 75:225-233, 1970.
130. Alexanian R. Correlation between erythropoietin production and excretion. Lab Clin Med 74:614-622, 1969.
131. Alexanian R. Erythropoietin and erythropoiesis in anemic man following androgens. Blood 33(4):564-572, 1969. PMID: 4887384.
132. Harris J, Alexanian R, Hersh E, Leary W. Hodgkin's disease complicated by infection with mycobacterium kansasii. Can Med Assoc J 101(4):231-234, 1969. PMCID: PMC1946123.
133. Alexanian R, Haut A, Khan AE, Lane M, McKelvey E, Migliore P, Stuckey W, Jr, Wilson H. Treatment for multiple myeloma: Combination chemotherapy with different melphalan dose regimens. JAMA 208(9):1680-1685, 1969. PMID: 5818682.
134. Alexanian R, Bergsagel D, Migliore P, Vaughn W. Melphalan therapy for plasma cell myeloma. Blood 31(1):1-10, 1968. PMID: 5638562.
135. Migliore P, Alexanian R. Monoclonal gammopathy in human neoplasia. Cancer 21(6):1127-1131, 1968. PMID: 5648048.
136. Samuels ML, Leary WV, Alexanian R, Howe CD, Frei E, III. Clinical trials with n-isopropyl-a-(2-methylhydrazina)-p-toluamide hydrochloride (Natulan) in malignant lymphoma and other disseminated neoplasia. Cancer 20:1187-1195, 1967.
137. Alexanian R, Vaughn WK, Ruchelman MW. Erythropoietin excretion in man following androgens. J Lab Clin Med 70(5):777-85, 1967. PMID: 6055763.
138. Adamson JW, Alexanian R, Martinez C, Finch CA. Erythropoietin excretion in normal man. Blood 28(3):354-364, 1966. PMID: 5918468.
139. Alexanian R. Urinary excretion of erythropoietin in normal men and women. Blood 28(3):344-353, 1966. PMID: 5918467.
140. Alexanian R, McAlexander RA, Donohue D. Effect of splenectomy on bone marrow cellularity in the dog. Tex Rep Biol Med 23(3):562-568, 1965. PMID: 5846268.
141. Alexanian R, Donohue D. Neutrophilic granulocyte kinetics in normal man. J Appl Physiol 20(4):803-808, 1965. PMID: 5838738.
142. Stegman R, Alexanian R. Solid tumors in multiple myeloma. Ann Intern Med 90(5):780-782, 1963. PMID: 434680.
143. Alexanian R, Porteous DD, Lajtha LG. Stem cell kinetics after irradiation. Int J Radiat Biol Relat Stud Phys Chem Med 7:87-94, 1963. PMID: 14073655.
144. Porteous R, Alexanian R, Lajtha LG. The fasted mouse in the study of bone marrow stem cell kinetics. Int J Radiat Biol Relat Stud Phys Chem Med 7:95-100, 1963. PMID: 14073656.

Invited Articles
1. Alexanian R, Weber D. Recent advances in treatment of multiple myeloma and Waldenstrom's macroglobulinemia. Biomedicine & Pharmacotherapy 55:550-552, 2001.
2. Crowley J, Jacobson J, Alexanian R. Standard dose therapy for multiple myeloma: The SWOG experience. Semin Hemat 38:203-208, 2001.
3. Dimopoulos M, Moulopoulos L, Datseris I, Weber D, Delasalle K, Gika K, Alexanian R. Imaging myeloma bone disease. Acta Oncologica 39:823-827, 2000.
4. Alexanian R, Anderson K, Barlogie B, Stirling D, Thomas D. Thalidomide in hematologic malignancies; future directions. Seminars in Hematology 37,(1, Suppl 3):35-39, 2000.
5. Alexanian R. Malignant plasma cell dyscrasias. M.D. Anderson Oncology Case Reports & Reviews 11(1):1-10, 1996.
6. Escalante C, Weiser M, Clayman G, Rolston K, Alexanian R. Invasive group a streptococcal infection. Cancer Bulletin 47:343-345, 1995.
7. Alexanian R, Dimopoulos M. Management of multiple myeloma. Semin Hematol 32(1):20-30, 1995. PMID: 7878475.
8. Alexanian R, Dimopoulos M, Delasalle K, Hester J, Champlin R. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells 13(2):118-121, 1995. PMID: 8520499.
9. Dimopoulos M, O'Brien S, Kantarjian H, Estey E, Keating M, Alexanian R. Treatment of Waldenstrom's macrglobulinemia with nucleoside analogue. Leukemia and Lymphoma 11(2):105-108, 1993.
10. Barlogie B, Alexanian R, Jagannath S. Plasma cell dyscrasias. JAMA 268(20):2946-2951, 1992. PMID: 1433713.
11. Alexanian R, Barlogie B, Ventura G. Chemotherapy for resistant and relapsing multiple myeloma. Eur J Haematol Suppl 42:145-148, 1990. PMID: 2576405.
12. Alexanian R, Barlogie B. New treatment strategies for multiple myeloma. Am J Hematol 35(3):194-198, 1990. PMID: 2220763.
13. Alexanian R, Barlogie B, Ventura G. Alexanian R, Barlogie B, Ventura G. Chemotherapy for resistant and relapsing multiple myeloma 43(51):140-144, 1989.
14. Barlogie B, Alexanian R. Second international workshop on myeloma: advances in biology and therapy of multiple myeloma. Cancer Res 49(24 Pt 1):7172-7175, 1989. PMID: 2479477.
15. Barlogie B, Epstein J, Alexanian R. Genotypic and phenotypic characteristics of multiple myeloma. Hematol Oncol 6(2):99-102, Apr-Jun, 1988. PMID: 2968948.
16. Barlogie B, Dicke K, Alexanian R. High dose melphalan for refractory myeloma. Hematol Oncology 6:167-172, 1988.
17. Fritshe H, Alexanian R. B2M Clinical usefulness in multiple myeloma. Abbott Diagnostics Educational Services, 1987.
18. Barlogie B, Alexanian R. Biology and therapy of multiple myeloma. Acta Haematol 78(1):171-174, 1987. PMID: 3124442.
19. Barlogie B, McLaughlin P, Alexanian R. Characterization of hematologic malignancies by flow cytometry. Anal Quant Cytol Histol 9(2):147-155, 1987. PMID: 3300685.
20. Alexanian R, Barlogie B. Recent advances in the biology of plasma cell myeloma (editorial). Hematologic Pathology 1:143-145, 1987.
21. Alexanian R. Long unmaintained remission in multiple myeloma. Am J Clin Oncol 9(5):210-214, 1986. PMID: 3776910.
22. Barlogie B, Alexanian R. Therapy of primary resistant and relapsed mltiple myeloma. Oncology 9:210-214, 1986.
23. Alexanian R. Evaluation and management of immunodeficiencies in multiple myeloma. World Health Communications, Inc., 1985.
24. Alexanian R, Barlogie B. Multiple myeloma current management. Tex Med 81(10):24-26, 1985. PMID: 4060076.
25. Smith L, Alexanian R. Treatment strategies for plasma cell myeloma. CA Cancer J Clin 36(4):214-220, Jul-Aug, 1985. PMID: 3926257.
26. Barlogie B, Raber MN, Johnson TS, Drewinko B, Alexanian R, Conrad F. Cytometry for diagnosis and treatment of cancer patients. Cancer Bulletin 35:40-46, 1983.
27. Alexanian R. Polychemotherapy for multiple myeloma. Proceedings of the 13th International Chemotherapy Congress, 1983.
28. Alexanian R. Treatment for multiple myeloma (editorial). Acta Haematologica 63:237-240, 1980.
29. Alexanian R. Multiple Myeloma (III): Chemotherapy. Cancer Bulletin 28:2-5, 1976.
30. Conklin R, Alexanian R. Clinical classification of plasma cell myeloma. Arch Intern Med 135(1):139-143, 1975. PMID: 1111462.
31. Alexanian R, Balcerzak S, Gehan E, Haut A, Hewlett J. Remission maintenance therapy for multiple myeloma. Arch Int Med 135:147-152, 1975.
32. Ruiz VC, Alexanian R. Recent advances in the treatment of multiple myeloma and macroglobulinemia. Postgraduate Medicine 5:179-185, 1974.
33. Alexanian R. Multiple Myeloma (II): Treatment for complications. Cancer Bulletin 25:15, 1973.
34. Alexanian R, Nadell J, Alfrey C. Oxymetholone treatment for the anemia of bone marrow failure. Blood 40(3):353-365, 1972. PMID: 5056967.
35. Aleanian R. Multiple Myeloma (I): Clinical and laboratory features. Cancer Bulletin 23:82-85, 1971.
36. Lajtha LG, Gilbert CW, Porteous DD, Alexanian R. Kinetics of a bone marrow stem cell population. Ann N Y Acad Sci 113:745-752, 1964. PMID: 14120523.
Other Articles
1. Bonnet J, Alexanian R, Salmon S, Bottomley R, Amare M, Haut A, Dixon D. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma. Cancer Treatment Reports 66:1267-1271, 1982.
2. Hokanson JA, Brown BW, Thompson JR, Drewinko B, Alexanian R. Tumor growth patterns in multiple myeloma. Cancer 39(3):1700-1712, 1977. PMID: 912647.

Abstracts
1. Thomas S, Delasalle K, Gavino M, Wang M, Alexanian R, Weber 2. 2-Cda-cyclophosphamide + rituximab for symptomatic Waldenstrom's macroglobulinemia. Haematologica 92(s2):228, 2007.
2. Wright J, Weber D, Thomas S, Wang M, Alexanian R, Hawkins V, Vadhan-Raj S. Characteristics of patients experiencing thromboembolic events during treatmetn for multiple myeloma. American Society of Hematology (Blood):557a (#1882), 2007.
3. Vadhan-Raj S, Weber D, Wang M, Giral S, Thomas S, Alexanian R, Zhou X, Patel P, Bueso-Ramos C, Newman R, Aggarwal B. Curcumin downregulates NF-kB and related genes in patients with multiple myeloma. American Society of Hematology (Blood):357a (#1177), 2007.
4. Wang M, Delasalle K, Thomas S, Zazilbash M, Giralt S, Weber D, Alexanian R. Early transplant is useful for older patients with multiple myeloma. Haematologica 92(s2):189, 2007.
5. Delasalle K, Wang M, Thomas S, Weber D, Alexanian R. High response rate with BCD combination for relapsing multiple myeloma. Haematologica 92(s2):158, 2007.
6. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortexomib-lenalidomide-dexamethasone. American Society of Hematology (Blood) 2007(3611):1057a, 2007.
7. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone. American Society of Hematology (Blood):1057a (#3611), 2007.
8. Giralt S, Thandi R, Qazilbash M, Mendoza F, Han F, Hosing C, Wang M, Thomas S, Alexanian R, Champlin R, Weber D. Retrospective comparison of transplant outcomes in patients with multiple myeloma according to induction therapy with thalidomide/dexamethasone with or with without bortezomb. American Society of Hematology (Blood):288a (#948), 2007.
9. Wang M, Zhou Y, Wang H, Yi Q, Zhang Y, Alexanian R, Kwak L, Du X. Trend and geographic variations in the incidence of Waldenstrom's Macroglobulinemia in the United States over 17 years from 1988 to 2004. American Society of Hematology (Blood):376B (#5174), 2007.
10. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson P, Niesvizky R, Alexanian R, Limentani S, Alsina M, Esseltine D, Anderson K. Updated survival analyses after prolonged follow-up of the Phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 143(4):798a (#2717), 2007. e-Pub 9/6/2008. PMID: 18783399.
11. Wang M, Delasalle K, Thomas S, Giralt S, Alexanian R. Complete remission represents the major surrogate marker of long survival in multiple myeloma. American Society of Hematology (Blood):123a (#403), 2006.
12. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Alexanian R, Yu Z, Zeldis J, Olesnycky M, Weber D. Lenalidomide in combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma. American Society of Hematology (Blood):1014a (#1014a), 2006.
13. Thomas S, Giralt S, Wang M, Delasalle K, Gavino M, Rankin K, Alexanian R, Weber D. Survival outcomes of patients receiving thalidomide-dexamethasone for previously untreated multiple myeloma. American Society of Hematology (Blood) 1019a:3569 (#3569), 2006.
14. Wang M, Talpaz M, Jagannath S, Chanan-Khan A, Alexanian R, Weber D, Gavino M, Estrov Z, Harris P, Picker D, Schlossman R, Tassone P, Anderson k, Munshi N. A phase I, multicenter dose escalation study of atiprimod in patients with refractory or relapsed multiple myeloma. American Society of Hematology (Blood):36a (#111), 2005.
15. Wang M, Alexanian R, Delasalle K, Weber D. Confirmation of the prognostic value of the international staging system for multiple myeloma. Hematology Journal:97 (#308), 2005.
16. Christoforidou A, Williams P, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Breitz H, Alexanian R, Champlin R, Giralt S. Impact of holmium-DOTMP on transplant outcomes for multiple myeloma. American Society of Hematology (Blood):128a (#426), 2005.
17. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. American Society of Hematology (Blood):231a (#784), 2005.
18. Weber DM, Wang LM, Delsalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol 97(4):71-72, 4/2004. PMID: 9217181.
19. Weber DM, Wang LM, Delsalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. International Multiple Myeloma Conference:71-72, 4/2004.
20. Weber D, Wang M, Delasalle K, Gavino M, Alexanian R. 2-chlorodeoxyadenosine and cyclophosphamide alone, or in a combination with rituximab, for previously untreated Waldenstrom's macroglobulinemia. American Society of Hematology (Blood):413a (#1476), 2004.
21. Moulopoulos L, Gika D, Delasalle K, Weber D, Anagnostopoulos M, Alexanian R. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. American Society of Hematology (Blood):415a (#1485), 2004.
22. Moulopoulos L, Gika D, Delasalle K, Weber D, Anagnostopoulos M, Alexanian R. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol 16(11):415a, 2004. e-Pub 8/8/2005. PMID: 16087694.
23. Alexanian R, Weber D, Wang M, Delsalle K. Thalidomide-dexamethason as primary treatment for multiple myeloma and role of added bortezomid. Multiple Myeloma:164, 2004.
24. Alexanian R, Wang L,Weber D, Delasalle K. Velcade, thalidomide, dexamethasone as primary therapy for newly-diagnosed multiple myeloma. American Society of Hematology (Blood):64a (#210), 2004.
25. Wang M, Alexanian R, Delasalle K, Weber D. Abnormal MRI of spine is the dominant risk factor for early progression of asymptomatic multiple myeloma. American Society of Hematology (Blood):687a (#2546), 2003.
26. Weber D, Wang M, Delasalle K, Alexanian R. Confirmation of prognostic value of model using B2M alone. American Society of Hematology (Blood):937a (#3491), 2003.
27. Alexanian R, Weber D, Delasalle K, Wang M, Giralt S, Champlin R. Frequency and impact of complete remission with intensive therapy for multiple myeloma. The Hematology Journal 4(Supp 1):S73, 2003.
28. Jagannath S, Barlogie B, Alexanian R, Anderson K. Limited experience from 2 phase 2 trials suggests Bortezomib can be given safely in myeloma patients with severe renal impairment. American Society of Hematology:234a (#828), 2003.
29. Richardson R, Alexanian R. Peripheral neuropathy following bortezomib therapy in patients with advanced multiple myeloma. American Society of Hematology (Blood):149a, 2003.
30. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in waldenstrom's macroglobulinemia. The Hematology Journal 4(Supp 1):S13, 2003.
31. Alexanian R, Weber D, Delasalle K, Wang M, Champlin R, Giralt S. Progressively reduced sensitivity of multiple myeloma to serial intensive therapies. American Society of Hematology (Blood):982a (#3654), 2003.
32. Weber DM, Wang LM, Delasalle KB, Smith T, Alexanian R. Risk factors for early progression of asymptomatic multiple myeloma. The Hematology Journal 4(Supp 1), 2003.
33. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide alone or with dexamethasone for resistant or relapsing multiple myeloma. The Hematology Journal 4(Sup 1), 2003.
34. Wang M, Weber D, Delasalle K, Rankin K, Gavino M, Alexanian R. Thalidomide-dexamethasone as primary therapy for multiple myeloma of high tumor mass. The Hematology Journal 4(Supp 1), 2003.
35. Richardson P, Barlogie B, Alexanian R, Anderson K. A Phase II multicenter study of proteasome inhibitor bortezomib (PS-341) in multiple myeloma patients with relapsed/refractory disease. American Society of Hematology (BLOOD):104a (#385), 2002.
36. Alexanian R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M. Asymptomatic Waldenstrom's disease. American Society of Hematology (Blood):604a (#2377), 2002.
37. Weber D, Albitar M, Delasalle K, Dey A, Rankin K, Gavino M, Walker P, Alexanian R. Correlation of peripheral blood plasma levels of angiogenesis factors with treatment using thalidomide-dexamethasone in previously untreated patients with multiple myeloma. American Society of Hematology (Blood):808a (#3193), 2002.
38. Weber D, Ginsberg C, Walker P, Aholendt M, Rankin K, Gavino M, Delasalle K, Alexanian R. Correlation of thrombotic/embolic events with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide or thalidomide-dexamethasone. American Society of Hematology (Blood):209a, 2002.
39. Alexanian R, Weber D, Delasalle K, Giralt S, Champlin R. Value of intensive therapy supported by autologous stem cells for primary resistant multiple myeloma. American Society of Hematology (Blood):180a (#672), 2002.
40. Wang M, Weber D, Fourney D, Burton A, Schomer D, Ahrar K, Gokaslan Z, Alexanian R. Value of vertobroplasty and kyphoplasty for painful vertebral compressions in multiple myeloma. American Society of Hematology (Blood):403a (#1565), 2002.

Book Chapters
1. Alexanian R, Dimopoulos M, Weber D, Delasalle K, Hester J, Champlin R. Intensive sequential therapy for VAD-resistant multiple myeloma. In: Leuk Lymphoma. 4, 5-6, 175-182, 1994. PMID: 7915163.
2. Alexanian R, Dimopoulos M, Weber D, Delasalle K, Hester J, Champlin R. Intensive sequential therapy for VAD-resistant multiple myeloma. In: Multiple Myeloma and Related Disorders. 4. Ares-Serono Symposia Publishers: Rome, 175-182, 1994.
3. Weber D, Alexanian R. Multiple myeloma and other plasma cell dyscrasias. In: Medical Oncology: A comprehensive review. PRR, Inc. Huntington, N.Y., 47-58, 1993.
4. Dimopoulos M, Moulopoulos A, Delasalle K, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. In: Blood. 6, 6, 359-369, 1992. PMID: 10979944.
5. Dimopoulos M, Moulopoulos A, Delasalle K, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. In: Hematol Oncol Clin North Am. 6, 2. W.B. Saunders Co. Philidelphia, 359-369, 1992. PMID: 1582978.
6. Alexanian R. Diagnosis and management of multiple myeloma. In: Neoplastic Diseases of the Blood, Second Ed. Churchill Livingston Inc., 453-465, 1991.
7. Alexanian R, Barlogie B. Chemotherapy for resistant multiple myeloma. In: Cancer chemotherapy: challenges for the future. 3. Excerpta Medica, 237-242, 1988.
8. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Genotypic and phenotypic diversity of plasma cell myeloma. In: The kidney in plasma cell dyscrasias. Kluwer Academic Publishers, 19-30, 1988.
9. Alexanian R, Barlogie B. Implications of renal failure in multiple myeloma. In: Cancer chemotherapy: challenges for the future. Kluwer Academic Publishers, 259-264, 1988.
10. Alexanian R. Multiple myeloma. In: Conn's Current Therapy, 39th. W.B. Saunders Co., 346-349, 1987.
11. Alexanian R. Diagnosis and management of multiple myeloma. In: Neoplastic Diseases of the Blood. Churchill Livingston Inc., 529-551, 1984.
12. Alexanian R. Plasma cell neoplasms and related disorders. In: Harrisons Principles of Internal Medicine, Tenth. McGraw-Hill Book Co., 363-367, 1983.
13. Alexanian R, Gutterman J, Levy H. Interferon treatment for multiple myeloma. In: Clin Haematol. II, 1. W.B. Saunders Co., Ltd. London, 211-220, 1982. PMID: 6176383.
14. Barlogie B, Latreille J, Alexanian R, Swartzengruber D, et al. Quantitative cytometry in myeloma research. In: Clinic in Haematology. II. W.B. Saunders Co., Ltd. London, 19-46, 1982.
15. Hersh E, Powell M, Gutterman J, Alexanian R. Effects of immunotherapy and chemotherapy on various host defence parameters. In: Fundamental Mechanisms in Human Cancer Immunology. Elsevier North Holland, Inc., 275-282, 1981.
16. McIntyre OR, Alexanian R, Cohen HJ, Landaw SA. Multiple myeloma, chronic leukemia, and polycythemia vera. In: Cancer Research, Impact of the Cooperative Groups. Mason Publishing USA, Inc., 85-101, 1980.
17. Alexanian R. Plasma cell neoplasms and related disorders. In: Hrrison's Principles of Internal Medicine, Ninth. McGraw-Hill Book Co., 1980.
18. Alexanian R. Plasma cell neoplasms. In: Current Problems in Cancer. III. Ed(s) 5. Yearbook Medical Publishers, 1978, 1978.
19. Alexanian R, Salmon S, Bonnet J, Gehan E, Haut A, Weick J. Chemoterapy for multiple myeloma. In: Recent Advances in Cancer Treatment. Raven Press, 19-38, 1977.
20. Alexanian R. Increased erythropoietin production in man. In: Kidney Hormones. I. Academic Press, 531-550, 1977.
21. Alexanian R. Multiple myeloma. In: Current Therapy, 29th. W.B. Saunders Co., 330-332, 1977.
22. Alexanian R. Plasma cell neoplasms. In: CA Cancer J Clin. 301, 1, 1700-1712, 1977. PMID: 812592.
23. Alexanian R. Plasma cell neoplasms. In: Medicine. 301. Medical Education (International) Ltd. London, 1700-1712, 1977.
24. Drewinko B, Alexanian R. Studies on the prolifereation kinetics of plasma cell myeloma. In: Pulse Cytophotometry: 11 International Symposium. European Press, 320-325, 1977.
25. Alexanian R, Hokanson J, Drewinko B. Tumor kinetics in multiple myeloma. In: Growth Kinetics & Biochemical Regulation of Normal & Malignant Cells. Williams and Wilkins Co., 629-641, 1977.
26. Alexanian R, Balcerzak s, Gehan EA, Haut A, Hewlett JS. Unmaintained remissions in multiple myeloma. In: Blood. 51, 6. Yearbook Medical Publishers, Inc., 155-171, 1975. PMID: 647110.
27. Alexanian R, Gehan E. Androgens and erythropoietin production. In: Endocrine and Non-Endocrine Hormone Producing Tumors. Yearbook Medical Publishers, Inc., 173-185, 1973.
28. Alexanian R. Monoclonal Gammopathies. In: Hematology, Principles and Practices. Yearbook Medical Publishers, Inc., 528-540, 1972.
29. Hersh EM, Curtis JE, Harris JE, McBride C, Alexanian R, Rossen R. Host defense mechanisms in lymphoma and leukemia. In: Leukemia-Lymphoma. Yearbook Medical Publishers, Inc., 149-167, 1970.
30. Alexanian R. Multiple Myeloma. In: Current Therapy, 22nd. W.B. Saunders Co., 256-258, 1970.
31. Alexanian R. Multiple myeloma: A nine-year experience with melphalan therapy at the M.D. Anderson Hospital. In: Leukemia-Lymphoma. Yearbook Medical Publishers, Inc., 305-316, 1970.

Letters to the Editor
1. Wang M, Alexanian R. Review of bortezomib, thalidomide, dexamethasone for relapsed multiple myeloma. Hematology & Oncology(3):918, 2005.
2. Bergsagel D, Wong O, Bergsagel P, Alexanian P, Anderson K, Kyle R, Raabe G. Benzene and multiple myeloma. Blood 95:1513, 2000.
3. Alexanian R, Anderson K, Barlogie B, Berenson J, Dalton W, Kyle R. In memoriam for Dr. Sydney Salmon. J Clin Oncol 18(1), 2000.
4. Weber D, Daliani D, Alexanian R. Clinical problem solving. New Eng J Med(333):1080, 1995.
5. Dimopoulos M, Luckett R, Alexanian R. Primary therapy of Waldenstrom's macroglobulinemia with paclitaxel. J Clin Oncol 12(12):1998, 1994. PMID: 7916042.
6. Dimopoulos M, Kantarjian H, Estey E, Alexanian R. 2-chlorodeoxyadenosine for multiple myeloma. Blood(81):868-869, 1993.
7. Weber D, Dimopoulos M, Alexanian R. Increased neurotoxicity with VAD-cyclosporin in multiple myeloma. Lancet 341(341):558-559, 1993. PMID: 8094795.
8. Dimopoulos M, Weber D, Estey E, Alexanian R. Primary treatment with 2-chlorodeoxyadenosine of low grade lymphomas that produce IgG or IgA immunoglobulin. Am J Hematol 43(4):326-327, 1993. PMID: 8103966.
9. Dimopoulos M, Kantarjian H, Estey E, Alexanian R. 2-chlorodeoxyadenosine in the treatment of multiple myeloma. Blood 80(80):1626, 1992. PMID: 1355673.
10. Dimopoulos M, Alexanian R. Irreversibility of drug resistance in VAD-refractory myeloma. Am J Hematol 40(40):154-155, 1992. PMID: 1585916.
11. Bergsagel D, Von Wussow P, Alexanian R, et al. Interferons in the treatment of multiple myeloma. J Clin Oncol 8(8):1444-1445, 1990. PMID: 2380763.
12. Barlogie B, Alexanian R, et al. Intermediate dose melphalan for refractory myeloma. Blood(74):1177, 1989.
13. Alexanian R. Ten year survival in multiple myeloma. Arch Intern Med 145(146):1637, 1986. PMID: 4062460.
14. Alexanian R. Ten-year survival in multiple myeloma. Arch Int Med(146):1637, 1986.
15. Alexanian R, Bodey G. Prednisone treatment of myeloma. Blood(63):970, 1984.
16. Alexanian R. Treatment for resistant myeloma. Your Patient & Cancer, 1984.
17. Alexanian R. The Monoclonal Gammopathies. Arch Int Med(138):655, 1978.
18. Hewell G, Alexanian R. Multiple myeloma in young persons. Ann Int Med(85):260-261, 1976.
19. Hewell G, Alexanian R. Multiple myeloma in young persons. Ann Intern Med 84(85):260-261, 1976. PMID: 1259287.
20. Alexanian R. Current therapy of multiple myeloma. Drug Therapy:102, 5/1975.

Manuals, Teaching Aids, Other Teaching Publications
1. Alexanian R. Myeloma Today. 3, No 8, 2000.
2. Alexanian R, Weber D, Delasalle K, Dimopoulos M. Course on Plasma Cell Dyscrasias: Athens, 163-166, 1998.
3. Alexanian R, Weber D, Delasalle K, Dimopoulos M. Course on Plasma Cell Dyscrasias: Athens, 357-359, 1998.
4. Alexanian R. Dial Access Medical Communications. Souther Medical Association, 3/1993.
5. Alexanian R, Dimopoulos M, Weber D, Delasalle K. International Course on Hematology: Mexico City, 63-72, 1993.
6. Alexanian R, Dimopoulos M, Weber D, Delasalle K. International Course on Hematology: Mexico City, 134-139, 1993.
7. Chaney H, Alexanian R. M.D. Anderson Anderson Hospital and Tumor Institute: Houston, 4/1976.
8. Alexanian R. The Network for Continuing Medical Education: New York, 3/1975.
9. Alexanian R. The Treatment of Multiple Myeloma. Dial Access Medical Communications, 1/1974.
10. Alexanian R. The treatment of multiple myeloma. 330, 7, 484-9, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8289856, 1/1974. PMID: 8289856.
11. Alexanian R. The Changing Spectrum of Monoclonal Gammopathies. Dial Access Medical Communications, 11/1973.

Last updated: 7/31/2009